← Back to headlines
Friedreich’s Ataxia Sufferers Face Setback as HSE Drugs Group Rejects Skyclarys Reimbursement
Patients suffering from Friedreich’s Ataxia have encountered a significant setback after the HSE Drugs Group rejected reimbursement for the drug Skyclarys. The recommendation will now proceed to a meeting of HSE senior management on August 25 for a final decision, offering a glimmer of hope.
11 Aug, 19:41 — 11 Aug, 19:41
